NephroGenex Inc

NephroGenex — Investor Presentation (March 2015)

28 slides from NephroGenex's investor presentation, Mar 26, 2015

  1. Slide 1: Corporate Presentation March 2015

    Corporate Presentation March 2015

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward- looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expe

  3. Slide 3: Corporate Overview

    Corporate Overview Late-stage company developing therapies that target the underlying cause of kidney disease  Oral Pyridorin (Phase 3) – an inhibitor & scavenger of pathogenic oxidative chemistries to slow progression of diabetic nephropathy (DN) – chronic  I.V. Pyridorin (Preclinical) – to treat

  4. Slide 4: The NephroGenex Team

    The NephroGenex Team Member Affiliation, Position Pierre Legault, CEO Sanofi-Aventis, President Worldwide Dermatology Eckerd, President Rite Aid, CAO OSI Pharmaceuticals, CFO Prosidion Ltd, CEO Board Member, NPS, Regado Biosciences, Cyclacel, Forest Labs J. Wesley Fox, Ph.D., President & CSO BioStra

  5. Slide 5: Financial Overview

    Cash  As of December 31, 2014 approximately $28.7 million in cash, cash equivalents and investments  Sufficient cash balance to finance operations into early 2016 NASDAQ: NRX (as of March 23, 2015)  Capital Structure ~ 10.3 M shares (8.9 M common, 1.3 M Options and 0.1 M warrants)  Average volum

  6. Slide 6: The NephroGenex Pipeline

    The NephroGenex Pipeline 6 Clinical Program / Indication Preclinical Phase 1 Phase 2 Phase 3 Worldwide Commercial Rights ORAL PYRIDORIN ® Diabetic Nephropathy I.V. PYRIDORIN ® Acute Kidney Injury Chronic oral bid 300 mg tablet targets pathogenic oxidative chemistries 2015 I.V. formulation for hospit

  7. Slide 7: Pathophysiology of Diabetic Nephropathy (DN)

    Pathophysiology of Diabetic Nephropathy (DN)  Pyridorin targets pathogenic oxidative chemistries and AGE formation  Pyridorin is an inhibitor and scavenger of these toxic carbonyls and AGEs (AGEs are recognized causative and promoting factors in DN)  DN is the leading cause of dialysis and chroni

  8. Slide 8: Pyridorin Mechanism of Action

    AGEs bind to receptors on the cells that comprise the glomerulus inducing pathological changes which adversely affect their filtration function. AGEs do not form and protein does not bind to receptors on the cells that comprise the glomerulus and therefore no pathology is induced. Pyridorin inhibits

  9. Slide 9: Promising early results for Intravenous Pyridorin

    Promising early results for Intravenous Pyridorin  Pyridorin targets specific pathogenic oxidative chemistries that emerge in diabetes  These pathogenic oxidative chemistries also emerge in hospital acquired acute kidney injury caused by: − Ischemia reperfusion injury − Contrast dye induced nephro

  10. Slide 10: Oral Pyridorin – Significant Market Potential

    Oral Pyridorin – Significant Market Potential DN patients progress from high risk, to early stage (microalbuminuria), to overt nephropathy (macroalbuminuria), to end stage renal disease (ESRD) and dialysis 19 M diagnosed diabetics in the US, of which 33% (6.3 M) exhibit kidney disease  2.8 M macroa

  11. Slide 11: Phase 2a PYR-205/207

    NephroGenex 6 Month Phase 2a PYR-205/207 Pyridorin at a 250 mg bid dose is well tolerated and slows the rate of SCr increase in moderate to advanced disease patients Two multi-center, randomized, double-blind, placebo-controlled trials  Number of centers: 20 (U.S., Belgium, United Kingdom, Canada,

  12. Slide 12: Phase 2b PYR-210

    NephroGenex 12 Month Phase 2b PYR-210 Established SOC patients approved by FDA for Phase 3 Pre-specified subgroup analysis Patients on established (or stable) standard of care (SOC) at screening exhibit a highly significant dose-dependent treatment effect in the FDA approvable RENAAL patient populat

  13. Slide 13: Phase Safety Trials

    NephroGenex Phase 2 Safety Trials Pyridorin was well tolerated, had a benign safety profile, and slowed the rate of SCr increase in patients on stable SOC at screening  No maximum dose tolerability toxicity found in animals & healthy humans  There were no differences between groups in SAEs, mortal

  14. Slide 14: PIONEER Pyridorin Phase 3 Trials Protocol

    PIONEER Pyridorin Phase 3 Trials Protocol Objective: Evaluate safety and efficacy of Pyridorin at a 300 mg twice daily dose compared to placebo to reduce the rate of renal disease progression due to type 2 diabetes mellitus Patient Population  Baseline SCr from 1.3 and less than 3.0 mg/dL (eGFR > 2

  15. Slide 15: PIONEER Trial Interim Analysis

    PIONEER Trial Interim Analysis Interim analysis expected middle of 2016 The Company expects to conduct an interim analysis after approximately 80 primary endpoint events have occurred The DSMB will be reviewing for safety The interim analysis will be event-based and conducted by an independent third

  16. Slide 16: PYRIDORIN Timeline

    PYRIDORIN Timeline Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Secured EMA support of study design & new SCr increase end point (Jan 2015) Expect completion IV PYR AKI preclinical results (Q2-Q3) Anticipate IND filing for IV PYR AKI (Q3) Anticipate launch of initial IV PYR AKI study (Q3) Expect completion of PIONEER Ph

  17. Slide 17: Exclusivity: Patents and New Chemical Entity

    Exclusivity Patents and New Chemical Entity (NCE) No composition of matter claim since this molecule already exists in the human body in microscopic quantities U.S.  Method of use (including patient population and dosage) patent December 2028 (with anticipated patent term extension)  Method of man

  18. Slide 18: Corporate Summary

    Corporate Summary Experienced management team focused on clinical success Diabetic nephropathy represents a large and growing unmet need Oral Pyridorin Pivotal Phase 3 program in DN initiated  Demonstrated benign safety profile in Phase 1 and Phase 2 a & b studies  Phase 3 program is studying the

  19. Slide 19: Appendix

    Appendix i) NephroGenex

  20. Slide 20: PIONEER Pyridorin Phase 3 Trials Protocol: Endpoints

    PIONEER Pyridorin Phase 3 Trials Protocol Primary end points: Evaluate Pyridorin 300 mg twice daily (BID) efficacy compared to placebo in reducing the rate of progression of renal disease due to type 2 diabetes mellitus. With time to the composite endpoint consisting of the earliest event amongst: 

  21. Slide 21: Pyridorin Safety Profile: PYR-210

    Pyridorin Safety Profile: PYR-210 Most Reported Adverse Events Most Reported Serious Adverse Events Pyridorin has a benign safety profile with the possible exception of a small increase in diarrhea and constipation with the higher dose of 300 mg bid  No meaningful differences between groups in AEs

  22. Slide 22: Pyridorin Phase 2a Program PYR-206

    Pyridorin Phase 2a Program PYR-206 Multi-center, randomized, double-blind, placebo-controlled trial  Number of centers: 46  Location of centers: U.S.  Dose: 50mg BID x 24 weeks  Study objectives: assess safety, tolerability and biological activity Diabetic patients with DN due to type 1 or type

  23. Slide 23: Clinical Results PYR-206 Post Hoc Analysis

    Clinical Results PYR-206 – Post Hoc Analysis Mild to Moderate Diabetic Nephropathy – Dose 50 mg BID Pyridorin at a 50 mg bid dose is well tolerated and slows the rate of SCr increase in mild to moderate disease patients Note: Virtually all patients on standard of care at screening – ACEI/ARB therapy

  24. Slide 24: Clinical Results PYR-205/207 Pre-Specified Subsets

    Clinical Results PYR-205/207 – Pre-Specified Subsets Moderate to Advanced Diabetic Nephropathy – Dose 250 mg bid Pyridorin at a 250 mg bid dose is well tolerated and slows the rate of SCr increase in mild to moderate disease patients Note: Virtually all patients on standard of care at screening – AC

  25. Slide 25: Clinical Results PYR-210 Pre-Approved Patient Population

    Clinical Results PYR-210 – Pre-Approved Patient Population Type 2 Diabetic Nephropathy Patients With and Without SOC 1at screening – 300 & 150 mg bid Patients on SOC at screening exhibit a highly significant dose-dependent treatment effect in the FDA approvable RENAAL patient population Patients not

  26. Slide 26: Urinary TGFb Analysis

    NephroGenex Phase 2 Urinary TGFb Analysis Placebo Pyridorin PYR-206 1 +14.4 pg/mg Baseline 34.4 pg/mg N=62 -9.3 pg/mg Baseline 37.9 pg/mg N=64 PYR-205/207 2 +14.2 pg/mg Baseline 41.6 pg/mg N=27 -9.7 pg/mg Baseline 39.4 pg/mg N=56 TGFb promotes renal fibrosis. As diabetic nephropathy progresses, urin

  27. Slide 27: Definition: Serum Creatinine and eGFR

    Definition  Serum Creatinine (SCr) – the level of creatinine, a by-product of muscle metabolism, circulating in the blood  Estimated Glomerular Filtration Rate (eGFR) – an estimate of the rate that the glomerulus filters blood based on circulating SCr levels corrected for age, sex, and race Compar

  28. Slide 28: Diabetic nephropathy competitive programs

    Company Agent Phase Program Status NephroGenex Inhibitor of pathogenic oxidative chemistries and AGE formation 3 Active AbbVie Endothelin receptor - antagonist 3 Active Janssen INVOKANA - SGLT2 inhibitor 3 Active Pfizer Chemokine CCR2/5 - receptor antagonist Phosphodiesterase type - 5 inhibitor 2 2

NephroGenex — Investor Presentation (March 2015) on 6ix